BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...Inc., which later became ConjuChem Inc.; and DrugAbuse Sciences Inc., which was later acquired by Elbion N.V....
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...Small molecules for alcohol and opiate abuse Not available Jan 2007 - assets acquired by elbion N.V....
BioCentury | Oct 25, 2010
Company News

Biotie, Pfizer deal

...was between Wyeth , now part of Pfizer, and elbion GmbH, which Biotie acquired from elbion N.V....
BioCentury | Sep 7, 2009
Company News

Biotie, Wyeth deal

...plus royalties. The original deal was between Wyeth and elbion GmbH, which Biotie acquired from elbion N.V....
BioCentury | Nov 24, 2008
Company News

Biotie, elbion deal

...BioTie completed its previously announced acquisition of elbion's elbion GmbH subsidiary for about 46.8 million shares...
...on BioTie's close of €0.30 on Nov. 13, the day before the deal closed. Certain elbion N.V....
...of €3.3 million ($4.2 million) (see BioCentury, Nov. 10). BioTie Therapies Corp. (HSE:BTH1V), Turku, Finland elbion N.V....
BioCentury | Nov 10, 2008
Company News

Biotie, elbion deal

...BioTie acquired elbion's elbion GmbH subsidiary for 46.8 million shares valued at €19.2 million ($23.9 million...
...elbion GmbH CFO Thomas Taapken and CSO Thomas Kronbach will retain their titles at BioTie. elbion N.V....
...III testing for alcohol addiction. The deal is expected to close on Nov. 18. Certain elbion N.V....
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...vector delivery technologies 1999 $11M PIPE, 1999 Institutional investors DrugAbuse Sciences, certain assets acquired by elbion...
BioCentury | Dec 24, 2007
Company News

elbion, Wyeth deal

...received an undisclosed milestone payment from WYE under a February deal to develop and commercialize elbion's...
...see BioCentury, Feb. 5). The payment was triggered by the identification of a preclinical candidate. elbion...
...a total of $110 million in payments over the life of the deal, plus royalties. elbion N.V....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...In-licenses or acquires FDA-approved and late-stage pharmaceutical products in therapeutic areas for U.S. specialty markets. elbion...
...In-licenses or acquires FDA-approved and late-stage pharmaceutical products in therapeutic areas for U.S. specialty markets. elbion...
BioCentury | Feb 26, 2007
Company News

elbion management update

elbion N.V. , Leuven, Belgium Business: Pulmonary, Neurology, Dermatology Hired: Koenraad Blot as CMO, formerly executive director of clinical research at Theratechnologies Inc. WIR Staff...
Items per page:
1 - 10 of 28
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...Inc., which later became ConjuChem Inc.; and DrugAbuse Sciences Inc., which was later acquired by Elbion N.V....
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...Small molecules for alcohol and opiate abuse Not available Jan 2007 - assets acquired by elbion N.V....
BioCentury | Oct 25, 2010
Company News

Biotie, Pfizer deal

...was between Wyeth , now part of Pfizer, and elbion GmbH, which Biotie acquired from elbion N.V....
BioCentury | Sep 7, 2009
Company News

Biotie, Wyeth deal

...plus royalties. The original deal was between Wyeth and elbion GmbH, which Biotie acquired from elbion N.V....
BioCentury | Nov 24, 2008
Company News

Biotie, elbion deal

...BioTie completed its previously announced acquisition of elbion's elbion GmbH subsidiary for about 46.8 million shares...
...on BioTie's close of €0.30 on Nov. 13, the day before the deal closed. Certain elbion N.V....
...of €3.3 million ($4.2 million) (see BioCentury, Nov. 10). BioTie Therapies Corp. (HSE:BTH1V), Turku, Finland elbion N.V....
BioCentury | Nov 10, 2008
Company News

Biotie, elbion deal

...BioTie acquired elbion's elbion GmbH subsidiary for 46.8 million shares valued at €19.2 million ($23.9 million...
...elbion GmbH CFO Thomas Taapken and CSO Thomas Kronbach will retain their titles at BioTie. elbion N.V....
...III testing for alcohol addiction. The deal is expected to close on Nov. 18. Certain elbion N.V....
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...vector delivery technologies 1999 $11M PIPE, 1999 Institutional investors DrugAbuse Sciences, certain assets acquired by elbion...
BioCentury | Dec 24, 2007
Company News

elbion, Wyeth deal

...received an undisclosed milestone payment from WYE under a February deal to develop and commercialize elbion's...
...see BioCentury, Feb. 5). The payment was triggered by the identification of a preclinical candidate. elbion...
...a total of $110 million in payments over the life of the deal, plus royalties. elbion N.V....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...In-licenses or acquires FDA-approved and late-stage pharmaceutical products in therapeutic areas for U.S. specialty markets. elbion...
...In-licenses or acquires FDA-approved and late-stage pharmaceutical products in therapeutic areas for U.S. specialty markets. elbion...
BioCentury | Feb 26, 2007
Company News

elbion management update

elbion N.V. , Leuven, Belgium Business: Pulmonary, Neurology, Dermatology Hired: Koenraad Blot as CMO, formerly executive director of clinical research at Theratechnologies Inc. WIR Staff...
Items per page:
1 - 10 of 28